Skip to main content
SpringerLink
Log in

Thallium-201SPECT assessment in the detection of recurrences of treated gliomas and ependymomas

  • Research Articles
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Introduction

The aim of this study was to establish the value of thalium-201 single-photon emission computed tomography (201Tl-SPECT) in the detection of recurrences in the follow-up of patients with treated primary neuroepithelial tumours.

Material and methods

Sixty-three201Tl-SPECT were performed in 36 patients with glioma (12 males, mean age of 46±13 years). All patients underwent surgery and adjuvant radiotherapy (and some of them received chemotherapy).

All patients were submitted to morphological neuroimaging techniques as well (and201 Tl-SPECT). Mean follow-up was 18.3±14.6 months.

Gold standard was based on clinical follow-up, therapeutical decisions (at least 4 months after201Tl-SPECT) and imaging features.

Results

Sensitivity and specificity of201Tl-SPECT to detect glioma recurrences were 90% and 100% respectively and 93% accuracy. Sensitivity and specificity for high grade tumours, were 100% respectively. Due to 4 false negatives, sensitivity and specificity for low grade gliomas were 78% and 100%. In the positive201Tl-SPECT group of patients overall survival was 13.64% at the end of the study. The negative201Tl-SPECT group had 84.62% overall survival at the end of the study (p=0.0003).

Conclusions

201Tl-SPECT is a valuable and noninvasive diagnostic procedure to detect recurrence or progression disease for treated gliomas and ependymomas.201Tl-SPECT has a good correlation with short term prognosis with excellent diagnostic accuracy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hoffman S, Propp JM, McCarthy BJ. Temporal trends in incidence of primary brain tumors in the United States, 1985–1999. Neuro-oncol. 2006;8:27–37.

    Article  PubMed  Google Scholar 

  2. Bernard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med. 2003; 33:148–62.

    Article  Google Scholar 

  3. Karim AB, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys. 2002;52:316–24.

    Article  PubMed  Google Scholar 

  4. Stupp R, Mason WP, Van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.

    Article  PubMed  CAS  Google Scholar 

  5. Vos MJ, Hoekstra OS, Barkhof F, et al. Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma. J Clin Oncol. 2003;21:3559–65.

    Article  PubMed  Google Scholar 

  6. Datta NR, Pasricha R, Gambhir S, et al. Comparative evaluation of201Tl SPECT and CT in the follow-up of irradiated brain tumors. Int J Clin Oncol. 2004;9:51–8.

    Article  PubMed  Google Scholar 

  7. Taki S, Kakuda K, Kakuma K, et al.201Tl SPET in the differential diagnosis of brain tumours. Nucl Med Commun. 1999;20: 637–45.

    Article  PubMed  CAS  Google Scholar 

  8. Higa T, maetani S, Yoichiro K, et al. Tl-201 SPECT Compared with Histopathologic Grade in the Prognostic Assessment of Cerebral Gliomas. Clin Nucl Med. 2001; 26:119–24.

    Article  PubMed  CAS  Google Scholar 

  9. Nagamachi S, Jinnouchi S, Nabeshima K, et al. The correlation between99mTc-MIBI uptake and MIB-1 as a nuclear proliferation marker in glioma: a comparative study with201Tl. Neuroradiology. 2001; 43:1023–30.

    Article  PubMed  CAS  Google Scholar 

  10. Martínez del Valle Torres MD, Gómez Río M, Rodríguez Fernández A, et al. Value of thallium201-SPECT in typing of brain space occupying lesions] Rev Esp Med Nucl. 2004;23:330–7.

    Article  PubMed  Google Scholar 

  11. Matheja P, Rickert C, Weckesser M, et al. Sequential scintigraphic strategy for the differentiation of brain tumours. Eur J Nucl Med. 2000;27:550–8.

    Article  PubMed  CAS  Google Scholar 

  12. Beauchesne P, Pedeux R, Boniol M, et al.99mTc-sestamibi brain SPECT after chemoradiotherapy is prognostic of survival in patients with high-grade glioma. J Nucl Med. 2004;45:409–13.

    PubMed  Google Scholar 

  13. Sun D, Liu Q, Liu W, et al. Clinical application of201Tl SPECT imaging of brain tumors. J Nucl Med. 2000;41:5–10.

    PubMed  CAS  Google Scholar 

  14. Katano H, Karasawa K, Sugiyama N, et al. Comparison of thallium-201 uptake and retention indices for evaluation of brain lesions with SPECT. J Clin Neurosci. 2002;9:653–8.

    Article  PubMed  Google Scholar 

  15. Vos MJ, Berkhof J, Postma TJ, et al. Thallium-201 SPECT: the optimal prediction of response in glioma therapy. Eur J Nucl Med Mol Imaging. 2006;33:222–7.

    Article  PubMed  Google Scholar 

  16. Sasaki M, Kuwabara Y, Yoshida T, et al. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med. 1998;25:1261–9.

    Article  PubMed  CAS  Google Scholar 

  17. Brunetti A, Alfano B, Soricelli A, et al. Functional characterization of brain tumors: an overview of the potential clinical value. Nucl Med Biol. 1996;23:699–715.

    Article  PubMed  CAS  Google Scholar 

  18. Van Laere K, Ceyssens S, Van Calenbergh F, et al. Direct comparison of18F-FDG and11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging. 2005;32:39–51.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiotherapy, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron, 119-129, 08035, Barcelona, Spain

    Anabel Mañes & Xavier Maldonado

  2. Nuclear Medicine Department, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron, 119-129, 08035, Barcelona, Spain

    Ana Paula Caresia, Joan Castell-Conesa, Montserrat Negre, Antoni Mestre & Gemma Cuberas

Authors
  1. Ana Paula Caresia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joan Castell-Conesa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Montserrat Negre
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antoni Mestre
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gemma Cuberas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anabel Mañes
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xavier Maldonado
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joan Castell-Conesa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caresia, A.P., Castell-Conesa, J., Negre, M. et al. Thallium-201SPECT assessment in the detection of recurrences of treated gliomas and ependymomas. Clin Transl Oncol 8, 750–754 (2006). https://doi.org/10.1007/s12094-006-0122-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-006-0122-9

Key words

Search

Navigation